Venarus® (Venarus®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceHesperidin + DiosminHesperidin + Diosmin
Similar drugsTo uncover
  • ANGIORUS
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Venarus®
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Venarus®
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Diovenges
    pills inwards 
    FORP, CJSC     Russia
    • Dosage form: & nbspfilm-coated tablets
    Composition:

    1 tablet contains:

    active ingredients: hesperidin (in terms of 100% substance) 100 mg, diosmin (in terms of 100% substance) 900 mg;

    Excipients: cellulose microcrystalline 124 mg, carboxymethyl starch sodium (sodium starch glycolate) 54 mg, gelatin 62 mg, talc 12 mg, magnesium stearate 8 mg;

    excipients for the shell: hypromellose (hydroxypropylmethylcellulose 41.4 mg, macrogol 6000 (polyethylene glycol 6000) 6.76 mg, sodium lauryl sulfate 0.2 mg, magnesium stearate 2.48 mg, titanium dioxide 7.88 mg, iron oxide red 0.6 mg, iron oxide yellow 0.68 mg.

    Description:

    The tablets covered with a film membrane of orange-pink color, biconvex, oblong with rounded ends, with a risk. On the cross-section, the core is from a grayish-yellow to a brownish-gray color.

    Pharmacotherapeutic group:Venotonizing and venoprotective agent
    ATX: & nbsp

    C.05.C.A.53   Diosmin in combination with other drugs

    Pharmacodynamics:

    Venarus ® has an angioprotective and venotonic effect.

    Reduces the extensibility of veins, increases their tone and reduces venous congestion; reduces permeability, fragility of capillaries and increases their resistance; improves microcirculation and lymph drainage. With systematic use reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature.

    The optimal "dose-effect" ratio is observed when taking 1000 mg per day.

    Pharmacokinetics:

    The main release of the drug occurs through the intestine. Through the kidneys on average about 14% of the taken amount of the drug is excreted. The half-life is 11 hours. The preparation Venarus ® is subject to active metabolism, which is confirmed by the presence of phenolic acids in the urine.

    Indications:

    Venus® is indicated for the treatment of symptoms of chronic venous diseases (elimination and alleviation of symptoms).

    Therapy of symptoms of venoznolymphatic insufficiency:

    - convulsions of the lower limbs;

    - sensation of heaviness and raspiraniya in the legs;

    - pain;

    - "fatigue" of the feet.

    Therapy of manifestations of venous-lymphatic insufficiency:

    - swelling of the lower extremities;

    - trophic changes in the skin and subcutaneous tissue;

    - Venous trophic ulcers.

    Symptomatic therapy of acute and chronic hemorrhoids.

    Contraindications:

    Hypersensitivity to the active ingredients or excipients included in the preparation.

    It is not recommended to take the drug to women during breastfeeding.

    Pregnancy and lactation:

    Pregnancy

    Experiments on animals did not reveal teratogenic effects. To date, there have been no reports of any side effects when the drug is used by pregnant women.

    Breastfeeding period

    Due to lack of data regarding the excretion of the drug with breast milk, it is not recommended to take the drug to women during breastfeeding.

    Influence on reproductive function

    Reproductive research toxicity showed no effect on reproductive function in rats of both sexes.

    Dosing and Administration:

    Inside.

    The recommended dose for venoznolymphatic insufficiency is 1 tablet per day, preferably in the morning, during a meal.The risk on the pill is intended exclusively for dividing in order to facilitate swallowing.

    The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

    The recommended dose for acute hemorrhoids is 3 tablets per day (according to 1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets per day (1 tablet in the morning and in the evening) for the next 3 days.

    The recommended dose for chronic hemorrhoids is 1 tablet per day.

    Side effects:

    The incidence of adverse reactions is as follows: very often (≥1 / 10 cases), often (≥1 / 100 and <1/10 cases) infrequently (≥1 / 1000 and <1/100 cases), rarely (≥1 / 10000 and <1/1000 cases) and very rarely (<1/10000 cases).

    Undesirable reactions, the frequency of development of which can not be estimated from available data, have the designation "frequency is unknown".

    From the central nervous system: rarely - dizziness, headache, general malaise.

    From the gastrointestinal tract: often - diarrhea, dyspepsia, nausea, vomiting; infrequently - colitis; frequency unknown - abdominal pain.

    From the skin: rarely - a rash, itching, hives; frequency unknown - isolated edema of the face, lips, eyelids, in exceptional cases, angioedema.

    If any of the unwanted reactions listed in the manual is aggravated, or if you notice other undesirable reactions not listed in the instructions, inform your doctor.

    Overdose:

    Cases of overdose are not described.

    If an overdose occurs, seek medical help immediately.

    Interaction:

    Not noted.

    It is necessary to inform the attending physician of all medications taken.

    Special instructions:

    Before you start taking Venarus ®, it is recommended that you consult with your doctor.

    In case of exacerbation of hemorrhoids, the appointment of Venarus ® does not replace the specific treatment of other anal disorders.

    Duration of treatment should not exceed the time specified in the section "Method of administration and dose". In the event that the symptoms do not disappear after the recommended course of therapy, you should undergo an examination with a proctologist who will choose further therapy.

    In the presence of violations of venous circulation, the maximum effect of treatment is provided by combining therapy with a healthy (balanced) way of life: it is desirable to avoid long stay in the sun, a prolonged stay on the legs, and it is also recommended to reduce excess body weight. Hiking and, in some cases, wearing special stockings, helps improve blood circulation.

    Immediately consult a doctor if your condition worsens during treatment or there is no improvement.

    Effect on the ability to drive transp. cf. and fur:

    Does not affect.

    Form release / dosage:

    Tablets, film-coated, 1000 mg.

    Packaging:

    For 9, 10 or 15 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    For 1, 2, 3, 4, 5, 6, 7, 8, 9 contour mesh packages together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-003561
    Date of registration:12.04.2016 / 21.11.2016
    Expiration Date:12.04.2021
    The owner of the registration certificate:OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspOBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSCOBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSCRussia
    Information update date: & nbsp04.02.2017
    Illustrated instructions
      Instructions
      Up